- Home
- CAST vs NYXH Comparison
CAST vs NYXH Comparison
Compare CAST & NYXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CAST | NYXH |
|---|---|---|
| Founded | 2011 | 2009 |
| Country | United States | Belgium |
| Employees | N/A | N/A |
| Industry | EDP Services | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 65.2M | 165.0M |
| IPO Year | 2020 | 2021 |
Fundamental Metrics
Financial Performance| Metric | CAST | NYXH |
|---|---|---|
| Price | $1.49 | $1.47 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $6.00 | ★ $9.33 |
| AVG Volume (30 Days) | ★ 905.2K | 261.0K |
| Earning Date | 06-26-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $213.98 |
| Revenue Next Year | N/A | $126.25 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.50 | $1.26 |
| 52 Week High | $12.20 | $6.87 |
Technical Indicators
Market Signals| Indicator | CAST | NYXH |
|---|---|---|
| Relative Strength Index (RSI) | 50.49 | 41.87 |
| Support Level | $1.24 | $1.28 |
| Resistance Level | $1.55 | $1.70 |
| Average True Range (ATR) | 0.12 | 0.08 |
| MACD | 0.05 | -0.01 |
| Stochastic Oscillator | 83.87 | 0.00 |
Price Performance
Historical ComparisonAbout CAST FreeCast Inc. Class A Common Stock
FreeCast Inc is a streaming technology company that provides platform-as-a-service solutions for television and digital video distribution. Its platform infrastructure supports telecom operators, internet service providers, broadcasters, municipalities, utilities, brands, and device manufacturers in deploying and managing digital media and streaming services.
About NYXH Nyxoah SA
Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.